NASDAQ:OMCL - Omnicell Stock Price, Forecast & News

Omnicell trades on the NASDAQ under the ticker symbol "OMCL."

Omnicell, Inc. (NASDAQ:OMCL) posted its earnings results on Thursday, October, 24th. The company reported $0.76 EPS for the quarter, topping the Thomson Reuters' consensus estimate of $0.71 by $0.05. The company earned $228.80 million during the quarter, compared to the consensus estimate of $231.86 million. Omnicell had a net margin of 6.28% and a return on equity of 11.90%. The company's revenue for the quarter was up 12.0% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.63 earnings per share. View Omnicell's Earnings History.

Omnicell is scheduled to release their next quarterly earnings announcement on Thursday, February 6th 2020. View Earnings Estimates for Omnicell.

7 analysts have issued 12 month price objectives for Omnicell's stock. Their forecasts range from $70.00 to $95.00. On average, they expect Omnicell's stock price to reach $85.57 in the next twelve months. This suggests that the stock has a possible downside of 1.1%. View Analyst Price Targets for Omnicell.

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omnicell in the last year. There are currently 3 hold ratings and 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Omnicell.

News headlines about OMCL stock have been trending somewhat positive recently, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Omnicell earned a media sentiment score of 1.8 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the stock's share price in the near term. View News Stories for Omnicell.

Omnicell saw a drop in short interest in December. As of December 13th, there was short interest totalling 2,100,000 shares, a drop of 7.9% from the November 28th total of 2,280,000 shares. Based on an average daily volume of 239,800 shares, the short-interest ratio is presently 8.8 days. Approximately 5.1% of the shares of the stock are sold short. View Omnicell's Current Options Chain.

Some companies that are related to Omnicell include Cerner (CERN), HMS (HMSY), Cortexyme (CRTX), Allscripts Healthcare Solutions (MDRX), HealthStream (HSTM), Vocera Communications (VCRA) and Computer Programs & Systems (CPSI).

Based on aggregate information from My MarketBeat watchlists, some companies that other Omnicell investors own include AT&T (T), AbbVie (ABBV), Netflix (NFLX), NVIDIA (NVDA), Alibaba Group (BABA), Bank of America (BAC), Johnson & Johnson (JNJ), Adobe (ADBE), Gilead Sciences (GILD) and Micron Technology (MU).

Omnicell's stock is owned by a variety of of institutional and retail investors. Top institutional investors include Peregrine Capital Management LLC (0.71%), Tributary Capital Management LLC (0.63%), Summit Creek Advisors LLC (0.63%), Scout Investments Inc. (0.43%), Rhenman & Partners Asset Management AB (0.23%) and Calamos Advisors LLC (0.13%). Company insiders that own Omnicell stock include Dan S Johnston, Gary S Petersmeyer, James T Judson, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps, Robin Gene Seim and Scott Peter Seidelmann. View Institutional Ownership Trends for Omnicell.

OMCL stock was sold by a variety of institutional investors in the last quarter, including Bowling Portfolio Management LLC, Tributary Capital Management LLC, Scout Investments Inc., Assenagon Asset Management S.A., Louisiana State Employees Retirement System, State of Alaska Department of Revenue and West Coast Financial LLC. Company insiders that have sold Omnicell company stock in the last year include Dan S Johnston, Gary S Petersmeyer, Joanne B Bauer, Jorge R Taborga, Joseph Brian Spears, Nhat H Ngo, Peter J Kuipers, Randall A Lipps and Scott Peter Seidelmann. View Insider Buying and Selling for Omnicell.

OMCL stock was purchased by a variety of institutional investors in the last quarter, including Summit Creek Advisors LLC, Peregrine Capital Management LLC, DNB Asset Management AS, Calamos Advisors LLC, Rhenman & Partners Asset Management AB, Rothschild Investment Corp IL, First National Bank of Omaha and SFE Investment Counsel. View Insider Buying and Selling for Omnicell.

Shares of OMCL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OMCL stock can currently be purchased for approximately $86.49.

Omnicell has a market capitalization of $3.63 billion and generates $787.31 million in revenue each year. The company earns $37.73 million in net income (profit) each year or $1.53 on an earnings per share basis. Omnicell employs 2,480 workers across the globe.View Additional Information About Omnicell.

The official website for Omnicell is http://www.omnicell.com/.

Omnicell's mailing address is 590 EAST MIDDLEFIELD ROAD, MOUNTAIN VIEW CA, 94043. The company can be reached via phone at 650-251-6100 or via email at [email protected]